The evolution of therapeutic modalities drives the adoption of single-use technologies.

Review of SUT Adoption in Biopharma Manufacturing

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

 Automating the Future of Fill/Finish

Topic

Articles

The standards organization’s annual drug shortages report finds drug shortages lasting longer and the number of discontinuations rising, but the number of shortages themselves have gone down.

USP Reports Drug Discontinuations on the Rise

Climate Principal Consultant, Nexio Projects

Pharmaceutical suppliers face growing pressure to calculate product carbon footprints as customer requirements and global regulations tighten.

CPHI Americas: The Business Case for Product Carbon Footprints in Pharma

Regulatory reform, patient access, and supply chain security were 3 of the key themes showcased this week on PharmTech.com.

PharmTech Weekly Roundup—June 5, 2026

Tom Sellig, Adare Pharma Solutions, shares how the CDMO is positioning for growth amid US reshoring and oral dose innovation trends.

Tom Sellig on CDMO Innovation and US Manufacturing Growth

At CPHI Americas, Delaware governor Matt Meyer outlined the state's biopharma vision: fostering workforce talent, industry collaboration, and regulatory speed to market.

A Pharma Manufacturing Blueprint from Delaware’s Innovation Vision 

John Muganga is senior manager, Regulatory Affairs at ICON plc.

CMC teams can align with Q5A(R2)’s updated guidance to shorten testing timelines and strengthen assurance of participant safety.

Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance

Erez Israeli is chief executive officer of Dr. Reddy's Laboratories.

Erez Israeli, chief executive officer of Dr. Reddy's Laboratories, provides insight on the company’s generic version of semaglutide, which entered the Canadian market in May 2026.

Generic GLP-1s Enter Canadian Market

FDA approves inhaled insulin Afrezza for children aged 6+, expanding pediatric diabetes care and highlighting inhaled biologics' manufacturing complexity.

Implications of Pediatric Inhaled Insulin Approval

This week's news and expert commentary shows that regulatory timelines are tightening, strategic capital is moving into new therapeutic categories, and long-standing operational gaps are demanding real solutions. 

PharmTech Weekly Roundup—May 29, 2026

Brian Drapeau is founder, GxPFrame and a cell and gene therapy manufacturing and quality systems consultant.

The cell and gene therapy manufacturing workforce is having to expand on deliverables while remaining under trained.